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Active Surveillance in Metastatic Renal Cell Cancer:
Missing a Chance for Cure?
We read with great interest the updated European
Association of Urology (EAU) guidelines on renal cell
carcinoma (RCC) described by Albiges et al [1]. According
to the EAU guidelines, immune checkpoint inhibition (ICI) is
recommended as the “backbone” of first-line treatment for
patients with clear-cell metastatic RCC (mRCC), including
patients with a favourable risk score according to the
International Metastatic Renal Cell Carcinoma Database
Consortium. For these patients, the recommended first-line
treatment is the combination of pembrolizumab and
axitinib, which consists of ICI (ie, PD-1 inhibition) and a
tyrosine kinase inhibitor targeting VEGFR. However, the
optimal timing for initiation of first-line ICI combinations is
not well defined, as active surveillance is still used,
especially for mRCC patients with a limited tumour burden
and few symptoms [2].
For decades, active surveillance has been the standard of
care in a subset of mRCC patients. In the era of ICI, the
question rises as to whether active surveillance is still
reasonable as first-line management of mRCC. First,
randomised clinical trials supporting active surveillance
for mRCC patients are lacking [2]. Second, patients with a
low tumour burden have a higher chance of tumour
response during PD-1 blockade [3]. Third, among mRCC
patients treated with first-line ICI combinations, complete
response rates of up to 9% have been observed [4] which is
unsurpassed for systemic therapy in mRCC. Fourth, tumour
responses during PD-1 blockade appear durable at 5 years
[5] and it is expected that these responses will persist
thereafter, as has been reported for ipilimumab mono-
therapy. This long-term survival emphasises the curative
potential of ICI. In order not to miss potential chances forPlease cite this article in press as: de Joode K, van der AAM. Re: L
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abandoned from current clinical practice.
As ICI is moving to earlier stages of mRCC, including the
favourable risk group, it is expected that an increasing
number of mRCC patients will experience durable
responses. In addition, an increasing number of mRCC
patients will be exposed to potential (severe) toxicity. The
optimal treatment duration of ICI for mRCC is currently not
well defined. Although responses are durable after early
discontinuation of ICI, the treatment is usually continued
until disease progression. Therefore, rules for a safe stop of
ICI need to be defined for mRCC patients with durable
tumour responses.
In the era of first-line ICI, we believe that active
surveillance needs reconsideration and should be reserved
for selected mRCC patients. Considering the pros and cons
of active surveillance versus first-line ICI, shared decision-
making is essential for treatment planning for mRCC
patients, in particular for patients with a low tumour
burden or minimal symptoms.
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